Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Imunoinstant is a specialized biotechnology division of Romvac Company S.A., based in Romania, focused on the development of hyperimmune egg-based biological products. The company leverages avian IgY antibody technology to produce treatments for various human pathologies, including antibiotic-resistant bacterial infections, viral diseases, and inflammatory conditions. Their core technology involves immunizing hens against specific pathogens to produce eggs rich in targeted antibodies, which are then processed into oral solutions, topicals, and food supplements. Imunoinstant's commercial portfolio addresses indications such as Helicobacter pylori infections, psoriasis, and respiratory tract infections. By providing a passive immunity approach, the company offers an alternative or adjunct to traditional antibiotic therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Imunoinstant.